Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally

Half Of Priority Reviews For Homegrown Firms

 
• By Brian Yang
  
Target shot opportunity dartboard performance how accurate can it be win looser miss fail flunk throw loss failure score on white background competition archery isolated 3d illustration
China's domestic firms get more new drug approvals, NMPA report shows • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

More from Asia